Skip to main content


Cutting-edge Long-Acting Injectable technology

BEPO® technology enables the development of leading-edge controlled release treatments

Designing first- or best-in-class therapeutic options

Our patented BEPO® technology makes it possible to control and guarantee the regular delivery of a drug at the optimal therapeutic dose for several days, weeks or months. At the time of the injection, the BEPO technology forms a deposit of polymers of a few millimeters under the skin for a systemic action, or locally for a targeted action. The deposit diffuses the active ingredient by resorbing for the desired duration, like a mini pump that would be injectable and bioresorbable.

In many indications

Once a medical need has been identified, the potential of the product validated and its technical feasibility evaluated positively, the Medincell team creates a prototype that meets the targeted specifications, in particular the duration of action and the dose of active ingredient to be released. For each product, a new polymer combination is created, making each formulation unique and exclusive.

BEPO® technology presentation

Inside BEPO®

Each BEPO® formulation is composed of a combination of diblock (DB) and triblock (TB) copolymers containing hydrophilic and water-soluble blocks (polyethylene glycol – PEG) linked with hydrophobic and amorphous blocks (Poly(D,L-lactic acid) – PLA) which precipitate in forming a depot when exposed to an aqueous environment.

The API is entrapped within the polymer matrix and is released thereafter by diffusion and following polymer degradation. The hygroscopy and consequently the API release kinetics from the depots can be fine-tuned by adjusting the hydrophilicity of the DB and TB and their relative ratio.